Li Zhan, Yin Songcheng, Zhang Lei, Liu Weiguang, Chen Bo, Xing Hua
Department of Breast Surgery.
Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning.
Onco Targets Ther. 2017 Feb 14;10:859-870. doi: 10.2147/OTT.S124733. eCollection 2017.
The association of CD133 overexpression with clinicopathological significance and prognosis in patients with breast cancer remains controversial. We thus performed a meta-analysis to evaluate the role of CD133 expression in the development and prognosis of breast cancer.
The databases PubMed, Embase, and Cochrane Library (updated to August 1, 2016) were searched. Pooled odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (95% CI) were used to evaluate the impact of CD133 expression on clinicopathological features, overall survival, and disease-free survival.
A total of 1,734 patients from 13 studies were subject to final analysis. The results showed a significant association between overexpression of CD133 and estrogen receptor status (OR 0.35, 95% CI 0.18-0.70), progesterone receptor status (OR 0.56, 95% CI 0.43-0.74), human epidermal growth factor-2 status (OR 1.81, 95% CI 1.33-2.45), lymph node metastasis (OR 1.98, 95% CI 1.34-2.92), and tumor histological grade (OR 1.79, 95% CI 1.26-2.54) in breast cancer. However, no significant correlation was found between upregulation of CD133 expression and onset age (OR 1.03, 95% CI 0.70-1.53) or tumor size (OR 1.29, 95% CI 0.80-2.09). Moreover, CD133-positive breast cancer patients had a higher risk of mortality (HR 1.91, 95% CI 1.21-3.03) and disease progression (HR 2.70, 95% CI 1.05-6.95).
This meta-analysis suggested that CD133 might be a predictor of clinical outcomes as well as prognosis and could be a potentially new gene therapy target for breast cancer patients.
CD133过表达与乳腺癌患者临床病理特征及预后的关系仍存在争议。因此，我们进行了一项荟萃分析，以评估CD133表达在乳腺癌发生发展及预后中的作用。
检索了PubMed、Embase和Cochrane图书馆数据库（更新至2016年8月1日）。采用合并比值比（OR）或风险比（HR）及95%置信区间（95%CI）来评估CD133表达对临床病理特征、总生存期和无病生存期的影响。
最终分析纳入了来自13项研究的1734例患者。结果显示，CD133过表达与乳腺癌的雌激素受体状态（OR 0.35，95%CI 0.18 - 0.70）、孕激素受体状态（OR 0.56，95%CI 0.43 - 0.74）、人表皮生长因子-2状态（OR 1.81，95%CI 1.33 - 2.45）、淋巴结转移（OR 1.98，95%CI 1.34 - 2.92）及肿瘤组织学分级（OR 1.79，95%CI 1.26 - 2.54）显著相关。然而，未发现CD133表达上调与发病年龄（OR 1.03，95%CI 0.70 - 1.53）或肿瘤大小（OR 1.29，95%CI 0.80 - 2.09）之间存在显著相关性。此外，CD133阳性的乳腺癌患者死亡风险（HR 1.91，95%CI 1.21 - 3.03）和疾病进展风险（HR 2.70，95%CI 1.05 - 6.95）更高。
这项荟萃分析表明，CD133可能是临床结局及预后的预测指标，并且可能成为乳腺癌患者潜在的新基因治疗靶点。
